ImmunoGen (IMGN) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings or view top-rated stocks.

5 brokers have issued 1 year price targets for ImmunoGen's stock. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they predict the company's share price to reach $14.86 in the next year. This suggests that the stock has a possible downside of 2.3%.
View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts.

ImmunoGen's stock was trading at $4.96 at the beginning of the year. Since then, IMGN stock has increased by 206.7% and is now trading at $15.21.
View the best growth stocks for 2023 here.

ImmunoGen saw a drop in short interest in May. As of May 15th, there was short interest totaling 15,580,000 shares, a drop of 32.6% from the April 30th total of 23,100,000 shares. Based on an average daily trading volume, of 6,540,000 shares, the short-interest ratio is presently 2.4 days.
View ImmunoGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMGN earnings forecast.

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Friday, April, 28th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The biotechnology company had revenue of $49.90 million for the quarter, compared to the consensus estimate of $21.63 million. ImmunoGen had a negative trailing twelve-month return on equity of 135.94% and a negative net margin of 198.88%. The business's revenue was up 31.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) earnings per share.

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC).

ImmunoGen updated its FY 2023 earnings guidance on Friday, April, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $108.34 million.

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.96%), State Street Corp (7.55%), Wellington Management Group LLP (4.36%), Maverick Capital Ltd. (3.48%), Geode Capital Management LLC (1.79%) and Artisan Partners Limited Partnership (1.41%).
View institutional ownership trends.

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IMGN stock can currently be purchased for approximately $15.21.

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.44 billion and generates $120.57 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

The company employs 106 workers across the globe.

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.